Valuation
P/E TTM
-7.55
P/E LYR
-5.14
P/B MRQ
2.46
P/S TTM
--
AI Analysis
- Valuation metrics reflect a market pricing the stock on future pipeline potential rather than current earnings, given the lack of profitability. The P/E ratio is negative and meaningless, the P/B ratio of 2.51 is not cheap, and the high P/S-TTM ratio of 10.96 indicates a premium valuation based entirely on anticipated future sales growth. The current price of $53.72 is towards the upper end of the recent trading range.
- Both the forward-looking dynamic PE (-5.14) and the trailing-twelve-month PE (-7.68) are negative due to net losses, rendering the traditional P/E ratio meaningless for valuation.
- The P/B ratio is 2.51, suggesting the market values the company at approximately 2.5 times its book value. For a biotech with a robust pipeline, this multiple can be justified by growth expectations, but it is not cheap.
- The P/S-TTM ratio is 10.96. This is a very high multiple, indicating the market is assigning significant value to each dollar of current sales based on anticipated future sales growth from new product launches.
- The last recorded price is $53.72. Over the last 60 trading days, the stock has traded in a wide range between a low of $39.50 and a high of $59.55, with the current price towards the upper end of this recent range.
- Given the company's transitional, pre-profitability stage, valuation is highly speculative and driven by clinical trial outcomes and regulatory milestones.
- A reasonable near-term price range, based on recent volatility and pending catalysts, is $45.00 - $62.00.
- A 12-month fundamental-based target price is challenging but framed around key events. Successful launch of its RSV vaccine could support a move toward the $65-$75 range. Pipeline setbacks could see the stock re-test support levels near $40.